GB0327840D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0327840D0
GB0327840D0 GBGB0327840.5A GB0327840A GB0327840D0 GB 0327840 D0 GB0327840 D0 GB 0327840D0 GB 0327840 A GB0327840 A GB 0327840A GB 0327840 D0 GB0327840 D0 GB 0327840D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0327840.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0327840.5A priority Critical patent/GB0327840D0/en
Publication of GB0327840D0 publication Critical patent/GB0327840D0/en
Priority to CA002546738A priority patent/CA2546738A1/en
Priority to RU2006123312/15A priority patent/RU2006123312A/ru
Priority to KR1020067010547A priority patent/KR20060122877A/ko
Priority to AU2004294282A priority patent/AU2004294282B2/en
Priority to PCT/EP2004/013587 priority patent/WO2005053661A2/en
Priority to CNA2004800355130A priority patent/CN1886157A/zh
Priority to US10/581,069 priority patent/US20070117833A1/en
Priority to EP04803369A priority patent/EP1819361A2/en
Priority to JP2006541869A priority patent/JP2007512381A/ja
Priority to BRPI0417146-2A priority patent/BRPI0417146A/pt
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0327840.5A 2003-12-01 2003-12-01 Organic compounds Ceased GB0327840D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
BRPI0417146-2A BRPI0417146A (pt) 2003-12-01 2004-11-30 combinações farmacêuticas
AU2004294282A AU2004294282B2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
RU2006123312/15A RU2006123312A (ru) 2003-12-01 2004-11-30 Фармацевтические композиции
KR1020067010547A KR20060122877A (ko) 2003-12-01 2004-11-30 제약 조합물
CA002546738A CA2546738A1 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
PCT/EP2004/013587 WO2005053661A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
CNA2004800355130A CN1886157A (zh) 2003-12-01 2004-11-30 药物组合
US10/581,069 US20070117833A1 (en) 2003-12-01 2004-11-30 Pharmaceutical compositions
EP04803369A EP1819361A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
JP2006541869A JP2007512381A (ja) 2003-12-01 2004-11-30 医薬的組み合わせ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds

Publications (1)

Publication Number Publication Date
GB0327840D0 true GB0327840D0 (en) 2003-12-31

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0327840.5A Ceased GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds

Country Status (11)

Country Link
US (1) US20070117833A1 (cg-RX-API-DMAC10.html)
EP (1) EP1819361A2 (cg-RX-API-DMAC10.html)
JP (1) JP2007512381A (cg-RX-API-DMAC10.html)
KR (1) KR20060122877A (cg-RX-API-DMAC10.html)
CN (1) CN1886157A (cg-RX-API-DMAC10.html)
AU (1) AU2004294282B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0417146A (cg-RX-API-DMAC10.html)
CA (1) CA2546738A1 (cg-RX-API-DMAC10.html)
GB (1) GB0327840D0 (cg-RX-API-DMAC10.html)
RU (1) RU2006123312A (cg-RX-API-DMAC10.html)
WO (1) WO2005053661A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
JP2009523149A (ja) * 2006-01-12 2009-06-18 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ
KR20140016439A (ko) * 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB0123025D0 (en) * 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2003106622A2 (en) * 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Also Published As

Publication number Publication date
AU2004294282B2 (en) 2009-05-07
BRPI0417146A (pt) 2007-03-06
CN1886157A (zh) 2006-12-27
EP1819361A2 (en) 2007-08-22
RU2006123312A (ru) 2008-01-20
WO2005053661A3 (en) 2005-12-29
US20070117833A1 (en) 2007-05-24
JP2007512381A (ja) 2007-05-17
CA2546738A1 (en) 2005-06-16
AU2004294282A1 (en) 2005-06-16
WO2005053661A2 (en) 2005-06-16
KR20060122877A (ko) 2006-11-30

Similar Documents

Publication Publication Date Title
TWI347941B (en) Organic compounds
IL175435A0 (en) Organic compounds
GB0402677D0 (en) Organic compounds
GB0301259D0 (en) Organic compounds
GB0303503D0 (en) Organic compounds
GB0326601D0 (en) Organic compounds
GB0325603D0 (en) Organic compounds
GB0307553D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0326602D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0301471D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0311971D0 (en) Organic compounds
GB0312086D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0304641D0 (en) Organic compounds
GB0303323D0 (en) Organic compounds
GB0303095D0 (en) Organic compounds
GB0301561D0 (en) Organic compounds
GB0303867D0 (en) Organic compounds
GB0324543D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)